Horizon Therapeutics [HZNP] vs Merck & Co [MRK] Detailed Stock Comparison
Horizon Therapeutics
NASDAQ
Loading...
Merck & Co
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Horizon Therapeutics wins in 4 metrics, Merck & Co wins in 13 metrics, with 0 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Horizon Therapeutics | Merck & Co | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 61.86 | 13.26 | Merck & Co |
| Price-to-Book Ratio | 5.01 | 4.40 | Merck & Co |
| Debt-to-Equity Ratio | 0.48 | 72.16 | Horizon Therapeutics |
| PEG Ratio | -16.29 | -0.75 | Horizon Therapeutics |
| EV/EBITDA | 24.08 | 8.41 | Merck & Co |
| Profit Margin (TTM) | 74.64% | 25.79% | Horizon Therapeutics |
| Operating Margin (TTM) | 16.83% | 37.47% | Merck & Co |
| EBITDA Margin (TTM) | 16.83% | 37.47% | Merck & Co |
| Return on Equity | 10.28% | 35.42% | Merck & Co |
| Return on Assets (TTM) | 5.72% | 13.01% | Merck & Co |
| Free Cash Flow (TTM) | N/A | $18.10B | N/A |
| Dividend Yield | N/A | 3.01% | N/A |
| 1-Year Return | -6.82% | -25.07% | Horizon Therapeutics |
| Price-to-Sales Ratio (TTM) | 7.34 | 3.38 | Merck & Co |
| Enterprise Value | $26.84B | $238.31B | Merck & Co |
| EV/Revenue Ratio | 7.40 | 3.75 | Merck & Co |
| Gross Profit Margin (TTM) | 76.72% | 77.50% | Merck & Co |
| Revenue per Share (TTM) | $16 | $25 | Merck & Co |
| Earnings per Share (Diluted) | $2.22 | $6.49 | Merck & Co |
| Beta (Stock Volatility) | N/A | 0.39 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Horizon Therapeutics vs Merck & Co Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Merck & Co | 1.50% | 3.75% | 7.06% | 12.24% | -4.27% | -11.90% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | -6.82% | 74.04% | 9.84% | 176.66% | 176.66% | 176.66% |
| Merck & Co | -25.07% | -2.12% | 6.90% | 65.38% | 161.82% | 231.32% |
Performance & Financial Health Analysis: Horizon Therapeutics vs Merck & Co
| Metric | HZNP | MRK |
|---|---|---|
| Market Information | ||
| Market Cap | $26.63B | $215.01B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 19,134,206 | 9,768,791 |
| 90 Day Avg. Volume | 8,460,695 | 11,514,587 |
| Last Close | $116.30 | $87.37 |
| 52 Week Range | $116.30 - $116.34 | $73.31 - $120.30 |
| % from 52W High | -0.03% | -27.37% |
| All-Time High | $39.49 (Jul 20, 2015) | $134.63 (Jun 24, 2024) |
| % from All-Time High | 194.50% | -35.10% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | -0.02% |
| Quarterly Earnings Growth | N/A | -0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.75% | 0.26% |
| Operating Margin (TTM) | 0.17% | 0.37% |
| Return on Equity (TTM) | 0.10% | 0.35% |
| Debt to Equity (MRQ) | 0.48 | 72.16 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $23.22 | $19.57 |
| Cash per Share (MRQ) | N/A | $3.45 |
| Operating Cash Flow (TTM) | $1.33B | $18.53B |
| Levered Free Cash Flow (TTM) | $1.81B | $15.56B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 3.01% |
| Last 12-Month Dividend | N/A | $2.39 |
Valuation & Enterprise Metrics Analysis: Horizon Therapeutics vs Merck & Co
| Metric | HZNP | MRK |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 61.86 | 13.26 |
| Forward P/E | 20.55 | 9.16 |
| PEG Ratio | -16.29 | -0.75 |
| Price to Sales (TTM) | 7.34 | 3.38 |
| Price to Book (MRQ) | 5.01 | 4.40 |
| Market Capitalization | ||
| Market Capitalization | $26.63B | $215.01B |
| Enterprise Value | $26.84B | $238.31B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.40 | 3.75 |
| Enterprise to EBITDA | 24.08 | 8.41 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.39 |
| Book Value per Share (MRQ) | $23.22 | $19.57 |
Financial Statements Comparison: Horizon Therapeutics vs Merck & Co
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HZNP | MRK |
|---|---|---|
| Revenue/Sales | N/A | $15.81B |
| Cost of Goods Sold | N/A | $3.56B |
| Gross Profit | N/A | $12.25B |
| Research & Development | N/A | $4.05B |
| Operating Income (EBIT) | N/A | $5.55B |
| EBITDA | N/A | $6.96B |
| Pre-Tax Income | N/A | $5.00B |
| Income Tax | N/A | $571.00M |
| Net Income (Profit) | N/A | $4.43B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HZNP | MRK |
|---|---|---|
| Cash & Equivalents | N/A | $8.63B |
| Total Current Assets | N/A | $35.50B |
| Total Current Liabilities | N/A | $25.17B |
| Long-Term Debt | N/A | $33.48B |
| Total Shareholders Equity | N/A | $48.40B |
| Retained Earnings | N/A | $66.10B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HZNP | MRK |
|---|---|---|
| Operating Cash Flow | N/A | $6.30B |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $1.17B |
| Debt Repayment | N/A | $-2.50B |
| Common Stock Repurchase | N/A | $-1.16B |
Short Interest & Institutional Ownership Analysis
| Metric | HZNP | MRK |
|---|---|---|
| Shares Short | N/A | 25.88M |
| Short Ratio | N/A | 1.92 |
| Short % of Float | N/A | 0.01% |
| Average Daily Volume (10 Day) | 19,134,206 | 9,768,791 |
| Average Daily Volume (90 Day) | 8,460,695 | 11,514,587 |
| Shares Outstanding | 229.00M | 2.53B |
| Float Shares | N/A | 2.49B |
| % Held by Insiders | N/A | 0.00% |
| % Held by Institutions | N/A | 0.81% |
Dividend Analysis & Yield Comparison: Horizon Therapeutics vs Merck & Co
| Metric | HZNP | MRK |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.39 |
| Last 12-Month Dividend Yield | N/A | 3.01% |
| 3-Year Avg Annual Dividend | N/A | $2.77 |
| 3-Year Avg Dividend Yield | N/A | 0.71% |
| 3-Year Total Dividends | N/A | $8.31 |
| Ex-Dividend Date | N/A | Mar 17, 2025 |